The combination of chemotherapy with a targeted therapy (gefitinib or osimertinib) in NSCLC patients has been proved to be superior to chemotherapy alone in the context of EGFR mutations [6,15,22]. Here, EGFR is linked to non-small cell lung carcinoma.